One-time therapy may be ‘transformative option' for treating deadly skin cancer
Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which involves isolating T cells – a type of white blood cell – from tumours and growing them in a lab before infusing them back into the patient where they can recognise and fight cancer.
It could become a 'transformative option' for patients with this type of skin cancer, experts said.
Cancer Research UK estimates that there are about 20,800 new cases of melanoma diagnosed in the UK every year.
Advanced melanoma, also known as stage four melanoma, means the disease has spread to other parts of the body.
The C-144-01 trial involved 153 patients from Europe and the US, and was led by The Royal Marsden NHS Foundation Trust.
At a five-year follow up, 19.7% of patients were still alive with no new or delayed side effects.
The trial also found that tumours shrank in almost four out of five (79.3%) patients, while one in 20 (5.9%) showed no evidence of cancer.
Dr Andrew Furness, a consultant medical oncologist who led the trial at The Royal Marsden NHS Foundation Trust, said: 'While current forms of immunotherapy have revolutionised the treatment of cancer in recent years, overall these benefit a minority rather than majority of treated patients.
'Results from this trial have shown that TIL therapy may change the outlook for people with advanced melanoma.'
Lifileucel is not yet approved for use in the UK, but was given the green light by the US Food and Drug Administration (FDA) for the treatment of advanced melanoma in February 2024.
Trials are also looking at using the TIL therapy in combination with pembrolizumab, sold under the brand name Keytruda, for people with advanced melanoma.
Keytruda works by targeting and blocking a protein known as PD-L1, which is found on T cells, to help the immune system fight cancer more effectively.
Dr Furness added: 'We're continuing our research into the use of TIL therapy, as well as other forms of cellular therapy, across a broader spectrum of cancers including advanced lung, liver, ovary, skin and testicular subtypes as well as soft tissue sarcoma.'
Study co-author James Larkin, consultant medical oncologist at The Royal Marsden and professor of precision cancer therapeutics at The Institute of Cancer Research, London, said: 'These significant results offer a compelling case for TIL therapy as a transformative option in melanoma care.
'The study demonstrates that for patients with few options left, a single infusion of lifileucel can provide a deep and lasting response and even complete remission in some cases. This marks a major advance in how we think about treating solid tumours.'
Zoe Phillips, 46, from Dorset took part in the TIL therapy trial at The Royal Marsden.
She was diagnosed with stage four melanoma in 2023 after previously being treated for skin cancer two years earlier.
'Six weeks after my first TIL therapy treatment, my scans showed that the tumours had completely disappeared,' Ms Phillips said.
'Before coming to The Royal Marsden I was told that I would probably die, so hearing that my treatment had been successful was amazing, I was over the moon.
'I come back to the hospital regularly for pembrolizumab immunotherapy treatment and currently still have no evidence of cancer.'
Findings from the C-144-01 trial have been presented at the American Society of Clinical Oncology (Asco) annual meeting in Chicago.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
6 hours ago
- Times
Scientists' discovery could stop breast cancer spreading
Scottish scientists have made a discovery that could help stop breast cancer spreading to other parts of the body. Experts at Cancer Research UK Scotland Institute and the University of Glasgow have found there are key metabolic changes that take place before tumours grow elsewhere. Their work is being hailed as a significant breakthrough because it is often cancer moving from the breast that kills patients. • How I told my sons that I had a rare form of breast cancer Researchers writing in the journal EMBO Reports said identifying the metabolic changes offered a vital window to intervene. Detecting these changes early could allow therapies to stop cancer cells moving around the body and forming tumours elsewhere. Dr Cassie Clarke, lead researcher, said: 'This study represents a major shift in how we think about preventing the spread of breast cancer. By targeting these metabolic changes as early as possible we could stop the cancer progressing and save lives.' About 56,800 people are diagnosed with breast cancer in the United Kingdom each year and 11,300 people lose their lives to the disease. Dr Catherine Elliott, Cancer Research UK's director of research, said: 'Discoveries in cancer research have made huge strides in making breast cancer a far more treatable disease than ever before. • Why the way we diagnose, label and treat cancer is changing 'However, metastasis — when cancer spreads — is a major factor in breast cancer becoming harder to treat, especially if the cancer returns months or even many years later. 'This discovery gives us new hope for detecting and stopping metastasis early and ensuring people have many more years with their families and loved ones.' The study focused on how breast cancer changes the immune system so it cannot tackle cancer cells as they begin their spread. The researchers found that cancer changes the metabolism — the way cells make and use energy — of specific immune cells, resulting in them releasing a prominent metabolite called uracil. Uracil is a molecule key to essential processes in the body which was found to help distant organs build a 'scaffold' to grow secondary tumours elsewhere in the body. By blocking an enzyme called uridine phosphorylase-1 (UPP1), which produces uracil, the scientists were able to stop this scaffold forming in mice and restore the ability of the immune system to kill secondary cancer cells to prevent metastasis. This opens the door to potentially powerful new tools to tackle cancer. Detecting uracil in the blood could help spot early signs of cancer spread, while blocking UPP1 with drugs could stop the spread before it starts. • The Times View: It is time to be optimistic about cancer The research was funded by Cancer Research UK, the Wellcome Trust, the Medical Research Council, Breast Cancer Now and Pancreatic Cancer UK. Simon Vincent, chief scientific officer at Breast Cancer Now, said: 'The researchers discovered that high levels of a protein called UPP1 may make some cancers, including breast cancer, more likely to spread to other parts of the body, where the disease becomes incurable. 'In mice, targeting the UPP1 protein before secondary breast cancer developed led to fewer secondary breast tumours and a boosted immune response in the lungs. 'Now we need more research to see if this new insight can be turned into new drugs that stop secondary breast cancer, and potentially other secondary cancers, in their tracks. With around 61,000 people living with secondary breast cancer in the UK, research like this is vital.' The team are further investigating exactly how UPP1 changes the behaviour of immune cells, exploring the role of immune cell metabolism in early breast cancer initiation, and testing the ability of drugs that block immune cell metabolism to prevent cancer occurring.
South Wales Argus
6 hours ago
- South Wales Argus
More people in Wales being screened for hepatitis B and C
In 2024, 121,874 people were screened for hepatitis B and 103,203 for hepatitis C, marking a respective 12 per cent and 14 per cent increase compared to 2023, according to the latest Blood Borne Virus (BBV) Annual Surveillance Report from Public Health Wales. Professor Daniel Thomas, consultant epidemiologist at Public Health Wales, said: "World Hepatitis Day is an opportunity to remind people that hepatitis B and C are preventable and treatable conditions. "Public Health Wales fully supports the WHO's goal to eliminate them as public health threats by 2030. "These viruses can remain in the body for many years without causing symptoms and many people may not realise they're infected." The report, covering data up to the end of 2024, identified 318 new hepatitis C cases and 305 new chronic hepatitis B cases. While deaths related to both viruses remain low, hepatitis C-related mortality increased in 2024. Professor Thomas said: "Our free, confidential Test and Post service makes it easier than ever to check your status from home. "I would urge anyone who thinks they may be at risk to get tested. "There is lots of information and support available which will provide peace of mind and allow you to access simple, effective treatment if needed." The at-home postal testing service allows individuals to order a kit online, take a finger-prick blood sample, and receive results by text message. Treatment for hepatitis C now consists of short tablet-based courses with high cure rates. Wales has already met nine of the World Health Organisation's 20 targets for hepatitis elimination. Public Health Wales continues to collaborate with NHS and community partners to improve harm reduction, prison testing, and access to services across the country.
Telegraph
12 hours ago
- Telegraph
We'll use AI to spot more prostate cancer, says Science Secretary
Artificial Intelligence will be harnessed to find hidden cases of prostate cancer, the Science Secretary has said. Peter Kyle told The Telegraph that the Government is investing £168m on initiatives to use public data better and one major goal is to improve cancer screening on the NHS. A world-leading initiative led by Cancer Research UK has been given £10m in funding to improve cancer screening methods by identifying the most at-risk people and offering them personalised tests. The funding will 'develop AI-powered tools that can predict cancer risk', Mr Kyle said, and could save thousands of lives a year. The Telegraph has launched a campaign calling for a targeted national screening programme for prostate cancer, which focusses on men who are at the greatest risk. This includes men over 50, black men, whose risk is twice that of white men, and those with a family history of prostate cancer. Steve McQueen, Bob Willis and Chris Hoy are some of the high-profile British men to be recently diagnosed with the condition. Around 55,000 men are diagnosed with prostate cancer annually in England and around 33 men a day die from the condition. Writing for The Telegraph alongside Stian Westlake, the executive chairman of the Economic and Social Research Council, Mr Kyle said: 'This funding will support work on a project linking health records to demographics, family history and behaviour to identify those at higher risk of this devastating illness, so that it can be treated early – potentially saving thousands of lives every year.' The plan is to create flexible national screening programmes which can pick up more cases in individuals who may otherwise be missed and diagnosed only when the cancer was incurable. Officials are hoping to replicate the success of BRCA1 genetic screening. Around one in 400 people has faulty BRCA genes, which give women a 60 per cent chance of developing breast cancer. This received widespread attention and became known as the 'Angelina Jolie gene' after the Hollywood actress underwent a double mastectomy after finding out she was a carrier in 2013. The NHS now offers genetic tests to high-risk groups, such as Jewish women, to catch as many cases early as possible. Mr Kyle said: 'Just as BRCA gene screening, heroically brought to the fore by campaigners including Angelina Jolie, revolutionised how we understand and manage the risk of hereditary breast cancer, this next generation of data-driven screening could do the same for more cancers, including prostate cancer.' Scientists running the scheme hope it can enable the NHS to offer more frequent cancer screening sessions or screening at a younger age to those at higher risk, while those at lower risk could be spared unnecessary tests. People identified as higher risk could also be sent for cancer testing faster when they go to their GP with possible symptoms. The wider Administrative Data Partnership will last until 2031 and try to repurpose data that already exists to make improvements to the judicial service, education, health and other public sectors. Combining, standardising and interpreting different datasets simultaneously is a daunting challenge for scientists owing to decades of independent data collection and little crossover. However, the Government believes that vast data reserves, combined with the power of AI computing, could transform healthcare. The cancer screening project will build new models over the next five years to merge relevant data as well as creating algorithms which will process it and ensure the results are accurate and reliable. Antonis Antoniou, the programme director and professor of cancer risk prediction at the University of Cambridge, said: 'The UK's strengths in population-scale data resources, combined with advanced analytical tools like AI, offer tremendous opportunities to link disparate datasets and uncover clues that could lead to earlier detection, diagnosis, and prevention of more cancers.' Dr David Crosby, the head of prevention and early detection research at Cancer Research UK, told The Telegraph: 'The single most important thing we can do to beat cancer is to find it earlier, when treatment is more likely to be successful. 'With half a million cancer cases per year expected in the UK by 2040, we need a major shift towards more accurate diagnosis and detection of early cancer. 'The Cancer Data Driven Detection programme will link health data sources together and build the powerful new tools doctors need to identify those at highest risk of cancer and prioritise resources towards them. 'Moving towards a preventative approach to healthcare will not be easy and will take time. Cancer Research UK's investment in the programme is an investment in the future of cancer care.' Data is the key to changing lives for the better By Peter Kyle and Stian Westlake For much of our everyday lives, data is king – from digital maps getting us from A to B, to health apps keeping our fitness and sleep in check, to even streaming platforms suggesting the next drama we might want to get stuck into. For this government, making good use of data is the difference between successful policies that are rooted in evidence, and those that rely on hope, luck or intuition, which no minister, legislator or council leader wants to rely on. Ultimately data is the bedrock of decision-making, ensuring policies, programmes and funding are doing what they are intended to do – changing lives for the better. Linking data from across government to the national pupil database for example can help to really dig into the source of inequalities that trap too many Brits from childhood through to the labour market – helping us to take targeted action in boosting social mobility and shattering glass ceilings. Or by better applying it in the justice system, we can understand patterns of reoffending, stopping career criminals from inflicting more misery on the law-abiding majority. And it can forecast the impact that this government extending the national living wage has on younger workers, so that millions more who put the hours in take home the pay they deserve. What unites all of these examples is that they were all made possible by UKRI's administrative data research UK partnership. It works to connect, and make sense of, the huge wealth of data that is generated by government services, bringing it to our world class researchers securely and with the public's privacy at heart since 2018. In short it has been demonstrating the role data can play in improving lives in as many ways as we can imagine and more. But we know we can go further and too many social and economic researchers – many of the very best of whom are right here in the UK – simply can't access the data they need. It is fragmented and siloed, held in different datasets by different public organisations. That means too many rely instead on insights from abroad, which while offering much, simply can't tell the full story of life in Britain in 2025. Accessing the raw resource of all that data and translating it into a form that researchers can use is no easy task, and while we need to grow our data science expertise, we also need to build relationships and make the case to other organisations that secure data sharing has the power to change lives. That is why UKRI is investing a further £168m to continue ADR UK's programme of work through to 2031. This includes continuing our partnership with Cancer Research UK to develop AI-powered tools that can predict cancer risk based on health records, family history and behaviour. Just as BRCA gene screening, heroically brought to the fore by campaigners including Angelina Jolie, revolutionised how we understand and manage the risk of hereditary breast cancer, this next generation of data-driven screening could do the same for more cancers, including prostate cancer. This funding will support work with organisations and charities like Cancer Research UK for example, on a project linking health records to demographics, family history, and behaviour to identify those at higher risk of this devastating illness, so that it can be treated early – potentially saving thousands of lives every year. The ADR will also offer learnings for and help us shape our new national data library, a central government resource designed to bring together existing research programmes and make it easier for policymakers and public bodies to access and use data securely to improve public services. As the incredible opportunities and challenges of technology like AI advance at unprecedented speeds and as we grapple with the fate of our planet as our climate changes, using data to drive policy for the generations to come has never been more important. This government is driven by a plan for change that will transform the lives of the British people, from growing our economy so that our payslips go further, to unlocking opportunity for everyone regardless of background, and building an NHS that is fit for the future and makes the most of the opportunities in new technology. Data can play a huge part in getting that right and targeting government support where it is needed most.
